Jinling Pharmaceutical Company Limited
Shenzhen Stock ExchangeTotal Valuation
Jinling Pharmaceutical Company Limited carries a market capitalization of 3.90B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.90B |
| Enterprise Value | 2.91B |
Share Statistics
Jinling Pharmaceutical Company Limited currently has 623.71M shares outstanding.
| Shares Outstanding | 623.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Jinling Pharmaceutical Company Limited trades at a trailing price-to-earnings ratio of 114.56. The price-to-sales ratio is 1.25, and the price-to-book ratio stands at 1.87.
| PE Ratio | 114.56 |
| PS Ratio | 1.25 |
| PB Ratio | 1.87 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | 22.76 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jinling Pharmaceutical Company Limited trades at an EV/EBITDA multiple of 2,913.21 and an EV/FCF ratio of 15.49. The EV/Sales ratio of 0.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2,913.21 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.86 |
| EV / EBITDA | 2,913.21 |
| EV / EBIT | 2,913.21 |
| EV / FCF | 15.49 |
Financial Position
Jinling Pharmaceutical Company Limited maintains a current ratio of 3.58, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.94, indicating elevated leverage, while an interest coverage ratio of -0.52 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.58 |
| Quick Ratio | 2.52 |
| Debt / Equity | 3.94 |
| Debt / EBITDA | -77.87 |
| Interest Coverage | -0.52 |
Financial Efficiency
Jinling Pharmaceutical Company Limited posts a return on equity of 1.62 and a return on invested capital of -0.02.
| Return on Equity (ROE) | 1.62 |
| Return on Assets (ROA) | 0.65 |
| Return on Invested Capital (ROIC) | -0.02 |
| Return on Capital Employed (ROCE) | 1.98 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 11.40 |
Taxes
Over the trailing twelve months, Jinling Pharmaceutical Company Limited has paid 16.76M in income taxes, reflecting an effective tax rate of 58.06.
| Income Tax | 16.76M |
| Effective Tax Rate | 58.06 |
Stock Price Statistics
Jinling Pharmaceutical Company Limited's stock has declined approximately -8.73362% over the past 52 weeks. The 50-day moving average sits at 7.24, while the 200-day moving average is 7.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -8.73362% |
| 50-Day Moving Average | 7.24 |
| 200-Day Moving Average | 7.31 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jinling Pharmaceutical Company Limited generated 3.37B in revenue and converted that into 36.92M in net income, yielding earnings per share of 0.02. EBITDA reached -2.44M, while operating income came in at -2.44M.
| Revenue | 3.37B |
| Gross Profit | 599.99M |
| Operating Income | -2.44M |
| Pretax Income | 28.86M |
| Net Income | 36.92M |
| EBITDA | -2.44M |
| EBIT | -2.44M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
Jinling Pharmaceutical Company Limited holds 2.56B in cash and equivalents against 189.92M in total debt, resulting in a net debt position of -1.18B. Total book value stands at 2.27B, with working capital of 2.62B providing operational flexibility.
| Cash & Cash Equivalents | 2.56B |
| Total Debt | 189.92M |
| Net Debt | -1.18B |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 3.65 |
| Working Capital | 2.62B |
Cash Flow
After subtracting -185.87M in capital expenditures, free cash flow totaled -185.87M - equivalent to -0.30 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -185.87M |
| Free Cash Flow | -185.87M |
| FCF Per Share | -0.30 |
Margins
Jinling Pharmaceutical Company Limited operates with a gross margin of 17.80, reflecting its pricing power and cost economics. The operating margin of -0.07 and net profit margin of 1.10 provide insight into operational efficiency.
| Gross Margin | 17.80 |
| Operating Margin | -0.07 |
| Pretax Margin | 0.86 |
| Profit Margin | 1.10 |
| EBITDA Margin | -0.07 |
Dividends & Yields
The company's payout ratio of -59.15 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | -59.15 |
| Shareholder Yield | -2.81 |
| FCF Yield | 4.39 |
Stock Splits
Jinling Pharmaceutical Company Limited's most recent stock split took place on July 10, 2006 with a 2:3 split ratio.
| Last Split Date | 7/10/2006 |
| Split Ratio | 2:3 |
Scores
Jinling Pharmaceutical Company Limited posts an Altman Z-Score of 3.62, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.62 |